07:00 Thu 07 Jan 2021
Destiny Pharma PLC - Destiny Pharma: Directors Dealings
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Directors Dealings
Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces the following Directors' dealings:
Details of the full notification received by the Company are set out below:
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | |
| 2. | Reason for the Notification | |
| a) | Position/status | Chairman |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Destiny Pharma plc |
| b) | LEI | 213800O9WH9Z38EHAC95 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Ordinary Shares of |
| Identification code | DEST GB00BDHSP575 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares |
| c) | Price(s) and volume(s) | 9,000 Ordinary Shares |
| d) | Aggregated information: Aggregated volume Price |
See 4c) above
|
| e) | Date of the transaction | |
| f) | Place of the transaction | London Stock Exchange, AIM Market |
Enquiries:
| Destiny Pharma plc | +44 (0) 1273 704 440 |
|
| |
| finnCap Limited - Nominated Adviser and Joint Broker | +44 (0) 20 7220 0500 |
|
| |
| WG Partners LLP - Joint Broker | +44 (0) 20 3705 9330 |
| | |
| Optimum Strategic Communications | +44 (0) 203 174 1789 |
| Mary Clark /
| |
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information, please visit https://www.destinypharma.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE
